Abstract:X-ray repair cross complementing group 1(XRCC1) polymorphisms have been implicated in interindividual variability of efficacy of platinum chemotherapy for treating non-small cell lung cancer (NSCLC); however, results of different studies have been inconsistent. We conducted a meta-analysis to investigate the association between polymorphisms in the XRCC1 gene and response rate of platinum chemotherapy in advanced NSCLC patients. Searches were performed on MEDLINE, PubMed, EMBASE, Chinese Biological Medicine Database, China National Knowledge Infrastructure, and Wangfang Data, covering all relevant studies published up to August 1, 2012. Statistical analyses were performed using the Revman 5.0 and STATA 10.0 software. Two polymorphisms, Arg399Gln (G>A) and Arg194Trp (C>T), were investigated in 19 studies, involving 2152 advanced NSCLC patients. For XRCC1 Arg399Gln, patients carrying two G alleles had a significantly increased response rate of platinum chemotherapy, when compared with those carrying the A allele [odds ratio (OR) = 2.05, 95% confidence interval CI = 1.62-2.60 for GG vs GA+AA]. Similarly, the AA carriers had a 54% decreased response rate compared with the G allele carriers (OR = 0.46, 95% CI = 0.30-0.70 for AA vs GA+GG). For XRCC1 Arg194Trp, patients carrying two C alleles had a 62% decreased response rate compared with those carrying either one or two variant T alleles (OR = 0.38, 95% CI = 0.30-0.48 for CC vs CT+TT). However, although TT carriers had a better response rate compared with the C allele carriers, the difference was not significant (OR = 1.27, 95% CI = 0.92-1.77 for TT vs CC+CT). Based on this meta-analysis, we conclude that XRCC1 polymorphisms are associated with treatment response to platinum chemotherapy in advanced NSCLC patients.

XPG Genetic Polymorphisms and Clinical Outcome of Patients with Advanced Non-Small Cell Lung Cancer under Platinum-Based Treatment: a Meta-Analysis of 12 Studies.

Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer

ASSOCIATION OF XRCC3 AND XPD751 SNP WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY IN ADVANCED NSCLC PATIENTS

Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients

Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.

Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients

Effect of Polymorphisms in Xpd on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients

Predictive Effect of XPA and XPD Polymorphisms on Survival of Advanced NSCLC Patients Treated with Platinum-Based Chemotherapy: a Three-Dimensional (3-D), Polyacrylamide Gel-Based DNA Microarray Method.

[XRCC1 and XPD Genetic Polymorphisms Predict Clinical Responses to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer].

Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.

Predictive Value of XRCC1 Gene Polymorphisms on Platinum-Based Chemotherapy in Advanced Non–Small Cell Lung Cancer Patients: A Systematic Review and Meta-analysis

Assessment of XPD Lys751Gln and XRCC1 T–77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy

Single nucleotide polymorphisms in XRCC1,XPD and platinum prognosis in non-small-cell lung cancer patients

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

XRCC1 Genetic Polymorphisms and Sensitivity to Platinum-Based Drugs in Non-Small Cell Lung Cancer: an Update Meta-Analysis Based on 4708 Subjects.

Association Between Single Nucleotide Polymorphisms (Snps) And Toxicity Of Advanced Non-Small-Cell Lung Cancer Patients Treated With Chemotherapy

Prognostic Significance of GSTP1, XRCC1 and XRCC3 Polymorphisms in Non-small Cell Lung Cancer Patients

Polymorphisms in the XRCC1 gene are associated with treatment response to platinum chemotherapy in advanced non-small cell lung cancer patients based on meta-analysis.

Xpa A23g Polymorphism is Associated with the Elevated Response to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer

Pharmacogenomics of Platinum-Based Chemotherapy Response in Nsclc: A Genotyping Study and A Pooled Analysis

[Polymorphisms in Nucleotide Excision Repair Genes XPC and XPD and Clinical Responses to Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer].